^
    Back
    Association details:
    Biomarker:CREB3L1 expression
    Cancer:Sarcoma
    Drug:doxorubicin hydrochloride (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Cancer
    Title:

    Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients

    Excerpt:
    ...the CREB3L1 expression level may predict the efficacy and survival of doxorubicin-based palliative chemotherapy for advanced soft-tissue sarcoma.
    DOI:
    10.7150/jca.28734